UBS Maintains Neutral on Edwards Lifesciences, Raises Price Target to $92

Benzinga · 1d ago
UBS analyst Danielle Antalffy maintains Edwards Lifesciences (NYSE:EW) with a Neutral and raises the price target from $90 to $92.